Ki 20227

Key Product Details

Product Description

Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC₅₀ values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.

Product Specifications for Ki 20227

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ki 20227

The following data is based on the product molecular weight 480.54.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.08 mL	10.40 mL	20.81 mL
5 mM	0.42 mL	2.08 mL	4.16 mL
10 mM	0.21 mL	1.04 mL	2.08 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 13 publications citing the usage of this product.

• Ohno The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 2007 PMID: 18085662
• Ohno A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 2006 PMID: 17121910
• Kubota M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 2009 PMID: 19398755

Product Documents for Ki 20227